Voxvoganan (LTX-109) trihydrochloride is a topical antimicrobial with high efficacy against S. aureus, exhibiting a MIC range of 2 to 4 μg/mL. It is used in research for treating bacterial skin infections, fungal infections, and nasal decolonization of MRSA [1] [2].

Voxvoganan trihydrochloride (LTX-109) is a chemically synthesized, first-in-class antimicrobial agent with a membrane-lysing mechanism similar to innate immune effector lytic peptides. It rapidly exhibits broad-spectrum bactericidal effects targeting the cell walls of various S. aureus strains, including multidrug-resistant ones [2]. Topically applied, it has a favorable safety profile, minimal bioavailability, and is effective against both mupirocin-susceptible and -resistant Staphylococcus aureus [3].